THE US Food and Drug Administration has approved Aemcolo (rifamycin), a newly released antibacterial drug indicated for the treatment of travellers' diarrhoea.
The condition is caused by non-invasive strains of E.coli, and is the most common travel-related illness, affecting an estimated 10 to 40% of travellers worldwide each year.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Nov 18
